# Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

> **NCT00121316** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 200 (—)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Pimecrolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00121316
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 200 (—)
- **Last updated:** 2008-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121316, "Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00121316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*